

The Longwood Herbal Task Force  
(<http://www.mcp.edu/herbal/default.htm>) and  
The Center for Holistic Pediatric Education and Research  
(<http://www.childrenshospital.org/holistic/>)

**Mistletoe (*Viscum album* L.)**

Margaret E. Loeper, MS

**Principal Proposed Uses:** Antineoplastic, immunostimulant

**Other Proposed Use:** Antihypertensive

***Overview***

The major use of mistletoe, *Viscum album*, is as a palliative cancer therapy. Historically it has been used to treat hypertension, epilepsy, exhaustion, anxiety, arthritis, vertigo, and degenerative inflammation of the joints. *V. album* is the European mistletoe species; it is the species used in the treatment of cancer and it will be the focus of this monograph. *Phoradendron*, or American mistletoe, is rarely used medicinally. Both species contain lectins, protein toxins, and polysaccharides. The scientific evidence regarding mistletoe's use as a palliative cancer therapy is inconclusive but promising. Mistletoe extracts are usually given parenterally and may cause inflammation at the injection site. Side effects from ingestion of mistletoe include gastrointestinal symptoms such as nausea, vomiting and diarrhea. Poisonings of children after mistletoe ingestion have been reported. There are no data on mistletoe's safety during pregnancy or lactation.

***Historical and Popular Uses***

Washington Irving described the tradition of stealing a kiss under this intriguing plant: "...the mistletoe, with its white berries," he said, is "hung up, to the imminent peril of all the pretty housemaids." At Christmas, the young men had the privilege of kissing ladies under mistletoe, "plucking each time a berry from the bush." Once all the berries had been plucked, no more kissing was allowed<sup>1</sup>.

First described by the Greek naturalist Theophrastus in the Third Century BC, mistletoe

became embedded in European rituals, folklore, and folk medicine. It was a sacred plant of the Celtic peoples who dominated Europe in the first millennium BC. The Gauls and the Celts called it “all-healer” or “cure-all”<sup>2</sup>.

Both European and American mistletoe contain toxic proteins which are similar in their chemical composition and produce similar effects, including hypotension, bradycardia, and vasoconstriction, in test animals<sup>3</sup>. Despite the popular belief that the two types of mistletoe have opposite effects, the stems and leaves of these plants contain similar phytochemicals<sup>4</sup>.

Anthroposophist Rudolf Steiner introduced the use of mistletoe extracts for the treatment of cancer in 1916<sup>5</sup>. Nowadays, Europeans include *V. album* in oncology therapies under the trade names Iscador<sup>®</sup> and Helixor<sup>®</sup>. The German Commission E has approved mistletoe as a treatment for degenerative and inflamed joints and as a palliative therapy for malignant tumors.

## ***Botany***

*Medicinal species: Viscum album*

*Common names:* All heal, bird lime, birdlime mistletoe, devil’s fuge, European mistletoe, golden bough, *herb de la croix* (Fr), *lignum crucis*, mystyldene, *visci albi fructus* (berries), *visci albi herba* (leaves), *visci albi stipites* (stem), and *viscum*<sup>6-10</sup>

*Botanical family:* Loranthaceae<sup>11</sup>

*Plant description:* Mistletoe is a semi-parasitic woody perennial commonly found growing on oaks and other deciduous trees<sup>7, 10</sup>. The plant is small, dioecious and shrubby, with oblong evergreen leathery entire leaves, clear dichasial branching and four-part flowers which form white sticky berries. It has a faint but characteristic odor and a bitter taste<sup>8</sup>. *Viscum* is most commonly seen on old apple, ash, and hawthorn trees; although mistletoe does not grow as well on oak trees, mistletoe from oak trees has traditionally been the most commonly used<sup>12</sup>. Mistletoe is propagated by birds that eat the berries and then excrete the seeds, or smear them on branches by wiping the sticky pulp off their beaks. Under proper conditions, the seeds germinate and the roots penetrate the branch of the host tree. Mistletoe is considered a semiparasitic plant because it synthesizes its own chlorophyll but depends on the host for its supply of water and minerals. The parts used medicinally are the leaves and stems.

Where it's grown: *V. album* is native to Europe and Asia. Imports originate in Bulgaria, Turkey, the former Yugoslavia, Albania and the former USSR<sup>8</sup>. *V. album* grows in Europe, northwest Africa, and southwest and central Asia and Japan; the Asian plant is a special variety, *V. album* (L) var. *coloratum*. *V. album* is grown in the US in Sonoma County, California; it is not imported<sup>13</sup>. American mistletoe grows in the eastern US from New Jersey to Florida, and from southern Ohio to southern Indiana. It is prevalent in Texas and some species are common in California and Oregon.

## ***Biochemistry***

### **Mistletoe (*Viscum album*): Active Chemical Constituents**

- Glycoproteins: mistletoe lectins I (galactoside-specific lectin), II, and III
- Proteins: viscotoxin
- Polysacchrides: galacturonan, arabinogalactan
- Alkaloids

Mistletoe's *lectins* are cytotoxic glycoproteins of approximately 10,000 molecular weight; they cause cells to agglutinate<sup>14</sup> and inhibit protein synthesis on the ribosomal level. The lectins, also known as viscumin or agglutinin, are dual chain molecules. Chain A inhibits protein synthesis and chain B activates macrophages and releases lymphokines from lymphocytes. Both the A and B chains of mistletoe lectin I also inhibit allergen-induced histamine release from leukocytes and collagen-induced serotonin release from platelets<sup>14</sup>. Lectins are structurally similar to two highly biologically active toxic proteins, ricin and abrin. The amounts and biological activity of *V. album* lectins are dependent on the host tree, manufacturing process, and time of harvest<sup>15</sup>.

*Viscotoxin* is a 46-amino acid peptide that damages cell membranes. Viscotoxin is found only in *V. album*. A similar constituent of *Phoradendron* is phoratoxin, a polypeptide about twice the weight of viscotoxin; it makes up 0.01% to 0.23% of *Phoradendron* leaves and stems<sup>16</sup>.

Various *polysaccharides* are thought to be involved in mistletoe's antineoplastic effects.

The leaves and stems contain esterified galacturonan, while the berries contain primarily arabinogalactan<sup>17</sup>.

*Alkaloids* are nitrogenous compounds that may contribute to mistletoe's cytotoxicity<sup>14</sup>.

## *Experimental Studies*

### **Mistletoe: Potential Clinical Benefits**

1. **Cardiovascular:** Hypertension
2. **Pulmonary:** none
3. **Renal and electrolyte balance:** none
4. **Gastrointestinal/hepatic:** none
5. **Neuro-psychiatric:** Epilepsy, exhaustion, vertigo, and anxiety: Traditional uses, no data.
6. **Endocrine:** none
7. **Hematologic:** Coagulant: Traditional use, no data.
8. **Rheumatologic:** Degenerative inflammation of the joints: Traditional uses; no data.
9. **Reproductive:** Abortifacient: Traditional use of *Phoradendron*, no data
10. **Immune modulation:** Immunostimulant
11. **Antimicrobial:** none
12. **Antineoplastic:** Antineoplastic
13. **Antioxidant:** none
14. **Skin and mucus membranes:** none
15. **Other/miscellaneous:** none

#### 1. **Cardiovascular:** Hypertension

- i. *In vitro data:* none
- ii. *Animal data:* Animal experiments are contradictory<sup>8</sup>.
- iii. *Human data:* A small case series in hypertensive adults treated with an herbal combination including *V. album* reported decreased blood pressure over 3-5 months. Since an herbal combination was used, it is difficult to interpret the effects of *V. album* alone<sup>18</sup>. There are no controlled trials evaluating *V. album* as a sole antihypertensive or comparing it to standard medications.

#### 2. **Pulmonary:** none

#### 3. **Renal and electrolyte balance:** none

#### 4. **Gastrointestinal/hepatic:** none

#### 5. **Neuro-psychiatric:** Epilepsy, exhaustion, vertigo, and anxiety: Traditional uses, no data<sup>10</sup>.

6. **Endocrine:** none
7. **Hematologic:** Coagulant: Traditional use, no data<sup>10</sup>.
8. **Rheumatologic:** Degenerative inflammation of the joints: Traditional use, no data<sup>8</sup>.
9. **Reproductive:** Abortifacient: *Phoradendron* has been recommended by herbalists as an abortifacient. No data are available.
10. **Immune modulation:** Immunostimulant
  - i. *In vitro data*: *V. album* agglutinin, a galactoside-specific plant lectin, induced apoptosis in human and murine lymphocytes and monocytes<sup>19</sup> and stimulated the proliferation of hematopoietic progenitor cells from healthy volunteers<sup>20</sup>. Mistletoe extracts induced proliferation of peripheral blood mononuclear cells; the strongest proliferation was seen with mistletoe from apple trees<sup>21</sup>. CD4+ T cells exposed to mistletoe extract displayed a significant increase in mean velocity, time locomoting, and migration distance<sup>22, 23</sup>.
  - ii. *Animal data*: none
  - iii. *Human data*: Case series and controlled trials in healthy adults and cancer patients support the use of mistletoe as an immunostimulant. In six healthy volunteers given mistletoe extract for eight weeks, there was pronounced proliferation of peripheral mononuclear cells<sup>24</sup>. See also **Antineoplastic**.
11. **Antimicrobial:** none
12. **Antineoplastic:** Antineoplastic
  - i. *In vitro data*: Mistletoe lectins cause both apoptosis and direct cytotoxicity<sup>25</sup>. Mistletoe lectins triggered apoptosis and enhanced the cytotoxic effect of chemotherapeutic drugs in leukemic cell lines<sup>26</sup>. *V. album* extracts had significant cytotoxic activity against cultured Hep-2 cells<sup>27</sup>. Mistletoe (Iscador<sup>®</sup>) inhibited the growth of rat hepatoma cells and Molt 4 cells in tissue culture<sup>28</sup>. Mistletoe lectins inhibited the growth of the Molt 4 tumor cell line; mistletoe lectin III was the most potent inhibitor<sup>29</sup>. Normal Molt 4 cells and three drug-resistant sublines were sensitive to the cytotoxic effects of Helixor<sup>®30</sup>. Mistletoe lectins I, II, and III exerted cytotoxic effects against six human breast cancer cell lines<sup>31</sup>. All mistletoe lectins inhibited leukemia cell growth; mistletoe lectin III was approximately ten times as cytotoxic as lectin I<sup>32</sup>.

Mistletoe extract significantly reduced the DNA damaging effects of carcinogens<sup>33</sup>.

In a study comparing 12 different mistletoe preparations on human leukocytes, the different preparations had varying effectiveness in inducing apoptosis and cytokine production. However, there was no correlation between the biological effects and the lectin content of these different preparations<sup>34</sup>.

- ii. *Animal data:* The *Viscum album* preparation Isorel<sup>®</sup> significantly restored the suppressed immune response of fibrosarcoma-bearing mice<sup>35</sup>.

Mistletoe preparations were effective in fighting solid tumors in eight of ten animal studies (seven in mice and three in rats). In two studies in mice, an extract of *V. album* coloratum (Korean mistletoe) significantly inhibited metastases including lung metastases<sup>36, 37</sup>. Iscador M<sup>®</sup>, an extract of *Viscum album*, inhibited metastatic colony formation induced by melanoma cells and reduced mortality in mice<sup>38</sup>. When Iscador<sup>®</sup> was administered to mice simultaneously with melanoma cells, lung nodule formation was inhibited by 92% and there was a 71% increase in life span<sup>38</sup>. Mistletoe lectin I significantly reduced tumor volume in rats with glioma<sup>39</sup>. It reduced tumor volume and lung and liver metastases in mice<sup>40</sup>. A single injection of the *V. album* preparation Isorel<sup>®</sup> reduced tumor size and caused tumor necrosis<sup>41</sup>. Another mistletoe preparation had antimetastatic activity against B16 melanoma lung colonization<sup>42</sup>.

In two negative studies in rats, mistletoe lectin I did not inhibit chemically-induced bladder cancer<sup>43, 44</sup>, and did not stimulate significant cellular immunological reaction in the wall of normal or cancerous urinary bladder<sup>43</sup>.

- iii. *Human data:* In case series and controlled trials, mistletoe had immunostimulant effects in cancer patients. Studies of its effects against cancer have had conflicting results.<sup>45-49</sup>

In several small case series, cancer patients given parenteral *V. album* preparations (in doses ranging from 0.5 ng/kg to 1 mg/kg) had increases in natural killer cells, T-helper cells, cytokine release, and peripheral blood mononuclear cells and lymphocytes. In one of these series, *V. album* treatment was associated with an improved quality of life<sup>48</sup>.

In a prospective randomized clinical trial of 35 patients with stage II-IV glioma, the treatment group received standard treatment plus a mistletoe extract (1 ng mistletoe lectin I/kg twice weekly) for three months beginning the day after surgery. The control group received standard therapy. The group receiving mistletoe had a significant up-regulation of cell counts (CD 3, CD-4, and CD-8 cells) and activities (CD-25, HLA/DR-positive cells) after three months compared to preoperative values, whereas the control group remained at preoperative values<sup>50</sup>.

In a prospective randomized clinical study of 47 breast cancer patients, those given mistletoe lectin I (0.5-1.0 ng/kg twice weekly) had enhanced activity of peripheral blood natural killer cells and T-lymphocytes<sup>15</sup>.

Studies of mistletoe's antineoplastic effects have had conflicting results.

A 59-year-old man with small cell lung carcinoma opted for Iscador<sup>®</sup> treatment rather than chemotherapy. He received subcutaneous Iscador once daily for five days, followed by oral Iscador 0.05–0.1 mg three times a day. The dose was progressively increased over a few weeks to achieve a maintenance dose of 5-10 mg three times a day. Subsequently radiotherapy was given and the patient lived five and a half years<sup>51</sup>

In 16 patients with stage III or IV ductal pancreatic carcinoma, Eurixor<sup>®</sup> (1 ng/kg) was administered twice weekly by subcutaneous injection. No partial or complete remissions were seen, but all but two patients claimed that mistletoe had a positive effect on their quality of life, with a decline only in the last few weeks of life<sup>52</sup>.

Fourteen patients with untreated stage IV renal adenocarcinoma and lung metastases were treated with escalating subcutaneous doses of Iscador<sup>®</sup> over three weeks. All the patients died, and no response to treatment was noted<sup>53</sup>.

In a retrospective analysis of 991 patients with colorectal cancer, mistletoe treatment significantly decreased the recurrence rate by 13% in those with lymph node negative disease, and by 23% in those with lymph node positive disease, in comparison to the untreated group. The survival probability as a result of the mistletoe therapy was 340 days longer than in the untreated group<sup>54</sup>.

13. **Antioxidant:** none

14. **Skin and mucus membranes:** none

15. **Other/miscellaneous:** none

## ***Toxicity and Contraindications***

*All herbal products carry the potential for contamination with other herbal products, pesticides, herbicides, heavy metals, and pharmaceuticals. This is particularly concerning with imports from developing countries.*

*Furthermore, allergic reactions can occur to any natural product in sensitive persons*

*Allergic reactions to mistletoe have been reported. A case of allergic rhinitis has been reported in a subject handling commercial mistletoe tea<sup>7</sup>*

*Potentially toxic compounds in mistletoe: Lectins, viscotoxin. All parts of the plant contain toxic compounds.*

*Acute toxicity: The German Commission E reports side effects such as chills, fever, headaches, angina and hypotension<sup>9</sup>. Ingestion of the American *Phoradendron* species usually causes acute gastrointestinal symptoms; lectins in both *Viscum* and *Phoradendron* species may cause delayed gastroenteritis. Ingesting concentrated mistletoe extracts may produce serious poisonings. Symptoms of acute toxicity include nausea, diarrhea, fixed and dilated pupils, diplopia, irritated conjunctiva, bradycardia, vasoconstriction, hypo- or hypertension, seizures, delirium and hallucinations. Cardiac arrest may occur. Deaths have occurred after ingestion of mistletoe tea taken as a tonic or abortifacient<sup>55-59</sup>.*

*In 300 cases of ingestion of mistletoe leaves or berries, the majority of patients remained asymptomatic and no deaths occurred; ingestion of up to three berries or two leaves is unlikely to produce serious toxicity<sup>7</sup>. Of the 1754 exposures to *Phoradendron leucarpum* reported between 1955-1992, no fatalities occurred, and 90.3% of those exposed remained asymptomatic. Children accounted for 92.1% of the cases<sup>60</sup>.*

*Intradermal injection of mistletoe may cause local inflammation, which can develop into necrosis<sup>8</sup>.*

*Chronic toxicity: Lectins are cytotoxic by inhibiting protein synthesis at the ribosomal level<sup>14, 61, 62</sup>. One case of hepatitis has been reported after ingestion of an herbal compound containing mistletoe, but no other instances of hepatotoxicity have been documented for mistletoe, and hepatitis has been documented with a common contaminant of scullcap, which was also in the herbal compound<sup>11</sup>.*

*Limitations during other illnesses or in patients with specific organ dysfunction:* Herbalists recommend avoiding mistletoe in patients with chronic progressive infections such as tuberculosis. Persons with heart disease should be monitored when using mistletoe, because it may cause hypertension or hypotension.

*Interactions with other herbs or pharmaceuticals:* Mistletoe may interfere with existing cardiac or immunosuppressant therapies<sup>11</sup>. Mistletoe is contraindicated in patients taking monamine oxidase (MAO) inhibitors because mistletoe preparations contain tyramine<sup>14</sup>.

*Safety during pregnancy and/or childhood:* Mistletoe has not been approved for pediatric use or use during pregnancy or lactation. It is contraindicated during pregnancy due to its speculated uterine stimulant action<sup>63</sup>.

## **Typical Dosages**

*Provision of dosage information does NOT constitute a recommendation or endorsement, but rather indicates the range of doses commonly used.*

*Doses are given for single agent use and must be adjusted when using remedies in combinations.*

*Doses may also vary according to the type and severity of the condition treated and individual patient conditions.*

*Typical adult doses:* Dosing parameters have not been established. Dosage depends on a number of factors including as the host tree, the preparation method, and standardization of the product to a particular constituent. Overdoses may cause poisoning.

*Tea (cold water infusion):* Cold water poured over 2.5 g (1 tsp.) of finely chopped drug and allowed to stand at room temperature for 10 to 12 hours, then strained. One to two cups daily. Mistletoe is also available in tea bags<sup>9</sup>

*Tincture (1:5 in 45% alcohol):* 1-4 ml daily<sup>12, 64</sup>.

*Dried aqueous extract (4:1):* 100-250 mg daily<sup>12</sup>

*Fluid extract (1:1 in 25% alcohol):* 1-3 ml three times daily<sup>11</sup>

*“Blood pressure tea”:* Mistletoe leaves, hawthorn leaves and flowers, and melissa leaves in equal parts. Two cups daily prepared by infusing 2 teaspoons of the mixture for five to ten minutes<sup>65</sup>.

*Oral Iscador<sup>®</sup>:* The following regime was used in one case study: 0.05-0.1 mg three times daily, then titrated over two weeks to 5-10 mg three times daily<sup>51</sup>.

*Parenteral preparations with standardized concentrations of mistletoe lectin I:* 0.29-12 ng/kg per day<sup>48, 66</sup>. In some studies the optimal dose was considered to be 1 nanogram per kilogram given twice weekly<sup>48, 52, 67</sup>.

*Parenteral fresh plant extract:* Based on whole fresh plant, dosages have ranged from 1 to 200 mg subcutaneously daily for up to two years. IV doses ranging from 0.09 to 0.33 mg per kg per day of fresh plant equivalent have been given as single or daily doses in 250 ml of saline<sup>49</sup>.

*Pediatric dosages:* Unknown

*Brand names:* European brands include: Iscador<sup>®</sup> and Helixor<sup>®</sup>, for subcutaneous use in cancer

treatment, and Plenosol<sup>®</sup>, for parenteral use for arthritic joints<sup>65, 68</sup>.

*Availability:* Injectable forms are available only in Europe. Powdered herb capsules are available in the US<sup>3</sup>. While Iscador<sup>®</sup> is not commonly used in the US, and is not approved for sale in the United States, but US doctors can order it directly from European manufacturers. American patients may also travel to Europe for Iscador treatment. Mistletoe therapy is available at clinics, hospitals, and private practices in the United Kingdom, Switzerland, West Germany, and the Netherlands<sup>2</sup>.

*Dosages used in combinations:* Mistletoe is a component of antihypertensive medications, cardiotonics and sedatives. Except for the mistletoe tea combination noted above, the mistletoe dosages used in these combinations are unknown<sup>8</sup>.

## REFERENCES

1. Bowman IA. The everlasting mistletoe and the cardiovascular system. *Herbal Gram* 1992; 26:16-21.
2. Walters R. Herbs and plants against cancer. *Journal of the American Holistic Veterinary Medical Association* 1994; 13:30-38.
3. Tyler VE. *The honest herbal : a sensible guide to the use of herbs and related remedies*. New York: Pharmaceutical Products Press, 1992:xviii, 375.
4. Anonymous. *Monographs on the medicinal uses of plants*. Exeter: European Scientific Cooperative on Phytotherapy, 1997.
5. Schulz V, Hansel R, Tyler VE. *Rational Phytotherapy: A Physicians' Guide to Herbal Medicine*. Berlin: Springer, 1997:306.
6. Peirce A. *The American Pharmaceutical Association practical guide to natural medicines*. New York: William Morrow and Company, Inc., 1999.
7. Anonymous. *The Lawrence Review of Natural Products*. In: Charles Dombek R, MA, ed. *Facts and Comparisons*. St. Louis: J.B. Lippencott Company, 1992.
8. Bissett NG. *Herbal drugs and phytopharmaceuticals*. Stuttgart: MedPharm CRC Press, 1994:566.
9. Blumenthal M. *The complete German Commission E monographs : therapeutic guide to herbal medicines*. Austin: American Botanical Council, 1998.
10. Fleming T. *PDR for herbal medicines*. Montvale, NJ: Medical Economics Company, Inc., 1998.
11. Newall CA, Anderson LA, Phillipson JD. *Herbal medicines : a guide for health-care professionals*. London: Pharmaceutical Press, 1996:ix, 296.
12. Murray MT. *The healing power of herbs : the enlightened person's guide to the wonders of medicinal plants*. Rocklin, CA: Prima Pub., 1995:xiv, 410.
13. Becker H. Botany of European Mistletoe (*viscum album* L). *Oncology* 1986; 43:2-7.
14. Franz H. Mistletoe Lectins and Their A and B Chains. *Oncology* 1986; 43:23-34.
15. Bussing A, Schietzel M. Apoptosis -inducing properties of *Viscum album* L. extracts from different host trees, correlate with their content of toxic mistletoe lectins. *Anticancer research* 1999; 19:23-28.
16. Andersson K, Johannsson M. Effects of viscotoxin on rabbit heart and aorta, and on frog skeletal muscle. *European Journal of Pharmacology* 1973; 23:223-231.
17. Jordan E, Wagner H. Structure and properties of polysaccharides from *Viscum album* (L). *Oncology* 1986; 43:8-15.
18. Fletcher-Hyde F. *Herbal Remedies Influencing the Heart and Circulation. Part 2 (Hypertension)*. *The British Journal of Phytotherapy* 1990; 1:14-16.
19. Hostanska K, Hajto T, Weber K, et al. A natural immunity-activating plant lectin, *Viscum album* agglutinin-I, induces apoptosis in human lymphocytes, monocytes, monocytic THP-1 cells and murine thymocytes. *Natural Immunity* 1996; 15:295-311.
20. Vehmeyer K, Hajto T, Hostanska K, et al. Lectin-induced increase in cologenic growth of haematopoietic

- progenitor cells. *European Journal Haematology* 1998; 60:16-20.
21. Fischer S, Scheffler A, Kabelitz D. Stimulation of the specific immune system by mistletoe extracts. *Anti-Cancer Drugs* 1997; 8:S33-S37.
  22. Nikolai G, Friedl P, Werner M, Niggeman B, Zanker K. Effect of a mistletoe extract (Iscador QuFrF) on viability and migratory behavior of human peripheral CD4+ and CD8+ T lymphocytes in three-dimensional collagen lattices. *In Vitro Cell Dev Biol Anim* 1997; 33:710-716.
  23. Schiltze J, Stettin A, Berg P. Demonstration of specifically sensitized lymphocytes in patients treated with an aqueous mistletoe extract (*Viscum album L.*). *Klin Wochenschr* 1991; 69:397-403.
  24. Stein G, Berg P. Modulation of cellular and humoral immune responses during exposure of healthy individuals to an aqueous mistletoe extract. *Eur Journal Med Res* 1998; 3:307-314.
  25. Bussing A, Suzart K, Bergman J, Pfuller U, Schietzel M, Schweizer K. Induction of apoptosis in human lymphocytes treated with *Viscum album L.* is mediated by the mistletoe lectins. *Cancer Letters* 1996; 1999:59-72.
  26. Bantel H, Engels I, Voelter W, Schilze-Osthoff K, Wesselborg S. Mistletoe lectin activates caspase-8/FLICE independently of death receptor signaling and enhances anticancer drug-induced apoptosis. *Cancer Research* 1999; 59:2083-90.
  27. Saenz M, Ahumada M, Garcia M. Extracts from *Viscum* and *Crataegus* are cytotoxic against larynx cancer cells. *Z Naturforsch [C]* 1997; 52:42-44.
  28. Ribereau-Gayon G, Jung M-L, DiScala D, Beck J-P. Comparison of the Effects of Fermented and Unfermented Mistletoe Preparations on Cultured Tumor Cells. *Oncology* 1986; 43:35-41.
  29. Dietrich J, Ribereau-Gayon G, Jung M, Franz H, Bech J, Anton R. Identity of the N-terminal sequences of the three A chains of mistletoe (*Viscum album L.*) lectins: homology with ricin-like plant toxins and single-chain ribosome-inhibiting proteins. *Anticancer Drugs* 1992; 3:507-11.
  30. Hulsen H, Mechelke F. In Vitro Effectiveness of a Mistletoe Preparation on Cytostatic-Drug-Resistant Human Leukemia Cells. *Naturwissenschaften* 1987; 74:1987.
  31. Schumacher U, Stamouli A, Adam E, Peddie M, Pfuller U. Biochemical, histochemical and cell biological investigations on the actions of mistletoe lectins I, II, and III with human breast cancer cell lines. *Glycoconj* 1995; 12:250-257.
  32. Ribereau-Gayon G, Jung M, Frantz M, Anton R. Modulation of cytotoxicity and enhancement of cytokine release induced by *Viscum album L.* extracts or mistletoe lectins. *Anticancer Drugs* 1997; 8:s3-s8.
  33. Bussing A, Jungmann H, Suzart K, Schweizer K. Suppression of sister chromatid exchange-inducing DNA lesions in clutered peripheral blood mononuclear cells by *Viscum album L.* *Journal of Experimental & Clinical Cancer Research* 1996; 15:107-114.
  34. Elsasser-Beile U, Lusebrink S, Grussenmeyer T, Wetterauer U, Schultze-Seemann W. Comparison of the effects of various clinically applied mistletoe preparations on peripheral blood leukocytes. *Arzneimittelforschung* 1998; 48:1185-1189.
  35. Jurin M, Zarovic N, Borovic S, Kissel D. *Viscum album L.* preparation Isorel modifies the immune reponse

- in normal and in tumour-bearing mice. *Anticancer Drugs* 1997; 8:S27-S31.
36. Yoon T, Yoo Y, Kang T, et al. Prophylactic effect of Korean mistletoe (*Visum album coloratum*) extract on tumor metastasis is mediated by enhancement of NK cell activity. *Int J Immunopharmacol* 1998; 20:163-172.
  37. Yoon T, Yoo Y, Choi O, et al. Inhibitory effect of Korean mistletoe (*Viscum album coloratum*) extract on tumor angiogenesis and metastasis of haematogenous and non-haematogenous tumor cells in mice. *Cancer Letters* 1995; 97:83-91.
  38. Antony S, Kuttan R, Kuttan G. Effect of *viscum album* in the inhibition of lung metastasis in mice induced by B16F10 melanoma cells. *J Exp Clin Cancer Res* 1997; 16:159-162.
  39. Lenartz D, Andermahr J, Plum G, Menzel J, Beuth J. Efficiency of treatment with galactoside-specific lectin from mistletoe against rat glioma. *Anticancer Research* 1998; 18:1011-1014.
  40. Beuth J, Ko H, Gabius H, Pulverer G. Influence of treatment with the immunomodulatory effective dose of the beta-galactoside-specific lectin from mistletoe on tumor colonization in BALB/c-mice for two experimental model systems. *In Vivo* 1991; 5:29-32.
  41. Zarkovic N, Zarkovic K, Grainca S, Kissel D, Jurin M. The *Viscum album* preparation Isorel inhibits the growth of melanoma B16F10 by influencing the tumor-host relationship. *Anticancer Drugs* 1997; 8:S17-S22.
  42. Weber K, Mengs U, Schwarz T, et al. Effects of a standardized mistletoe preparation on metastatic B16 melanoma colonization in murine lungs. *Arzneimittelforschung* 1998; 48:497-502.
  43. Kunze E, Schulz H, Gabius H. Inability of galactoside-specific mistletoe lectin to inhibit N-methyl-N-nitrosourea-induced tumor development in the urinary bladder of rats and to mediate a local cellular immune response after long-term administration. *J Cancer Res Clin Oncol* 1998; 124:73-87.
  44. Kunze E, Schulz H, Ahrens H, Gabius H. Lack of an antitumoral effect of immunomodulatory galactoside-specific mistletoe lectin on N-methyl-N-nitrosourea-induced urinary bladder carcinogenesis in rats. *Exp Toxicol Pathol* 1997; 49:167-180.
  45. Beuth J, Stoffel B, Ko H, Tunggal L, Pulverer G. Immunoactive effects of various mistletoe lectin-1 dosages in mammary carcinoma patients. *Arzneimittelforschung* 1995; 45:505-507.
  46. Beuth J, Ko H, Gabius H, Burcher H, Oette K, Pulverer G. Behavior of lymphocyte subsets and expression of activation markers in response to immunotherapy with galactoside-specific lectin from mistletoe in breast cancer patients. *Clinical Investigations* 1992; 70:658-661.
  47. Hajto. Immunomodulatory effects of Iscador: A *Viscum album* preparation. *Oncology* 1986; 43:51-65.
  48. Heiny B, Beuth J. Mistletoe extract standardized for the Galactoside-Specific lectin (ML-1) induces beta-endorphin release and immunopotentiality in breast cancer patients. *Anticancer Research* 1994; 14:1339-1342.
  49. Kovacs E, Hajto T, Hostanska K. Improvement of DNA Repair in Lymphocytes of Breast Cancer Patients Treated with *Viscum album* Extract (Iscador). *European Journal of Cancer* 1991; 27:1672-1676.
  50. Lenartz D, Stoffel B, Menzel J, Beuth J. Immunoprotective Activity of the Galactoside-Specific Lectin from

- Mistletoe after Tumor Destructive Therapy in Glioma Patients. *Anticancer Research* 1996; 16:3799-3802.
51. Bradley G, Clover A. Apparent response of small cell lung cancer to an extract of mistletoe and homoeopathic treatment. *Thorax* 1989; 44:1047-1048.
  52. Friess H, Beger H, Kunz J, Funk N, Schilling M, Buchler M. Treatment of Advanced Pancreatic Cancer with Mistletoe: Results of a Pilot Trial. *Anticancer Research* 1996; 16:915-920.
  53. Kjaer M. Mistletoe (Iscador) Therapy in Stage IV Renal Adenocarcinoma. *Acta Oncologica* 1989; 28:489-494.
  54. Hellan J, Danmayer E, Hellan M. Importance of complementary medicine during the treatment of oncological patients- SHown by the exa mple of colorectal carcinoma. *Deutsche Zeitschrift fur Onkologie* 1995; 27:85-94.
  55. Dixon. *British Medical Journal* 1874; 1:255.
  56. Osol A, Farrar G. *US Dispensatory*. Philadelphia: JB Lippencott Company, 1955:1928-1929.
  57. Rhoads P, Banner W, Tong T, al e. Unanticipated neurologic symptoms following bee pollen. *Bulletin from the Arizona Poison Information Center*. Tucson, Arizona, 1986.
  58. Moore. Mistletoe poisoning: a review of the available literature and the report of a case of probable fatal poisoning. *Journal of South Carolina Medical Association* 1969; 59:269-271.
  59. Petkov. Plants with hypotensive, antiatheromatous, and coronary-dilating actions. *American Journal of Chinese Medicine* 1979; 7:197-236.
  60. Krenzeloek EPJ, TD; Aronis, John. *American Mistletoe Exposures*. *American Journal of Emergency Medicine* 1997; 15:516-520.
  61. Anon. Baleful Mistletoe. *Lancet* 1982; 1:295.
  62. Salzer. Pleura carcinosis. Cytomorphological findings with the mistle preparation Iscador and other pharmaceuticals. *Oncology* 1986; 43:66-70.
  63. Brinker FJ. *Herb contraindications and drug interactions : with appendices addressing specific conditions and medicines*. Sandy, Or.: Eclectic Institute, 1997:146.
  64. Hoffman D. *The complete illustrated holistic herbal*. Rockport, MA: Element Books Inc., 1996.
  65. Weiss RF. *Herbal medicine*. Gothenburg, Sweden: AB Arcanum, 1988.
  66. Hajto T, Hostanska K, Gabius H. Modulatory potency of the beta-galactoside-specific lectin from mistletoe extract (Iscador) on the host defense system in vivo in rabbits and patients. *Cancer Research* 1989; 49:4803-4808.
  67. Hauser. Unproven methods in oncology. *European Journal of Cancer* 1991; 27:1549-1551.
  68. Wagner H, Jordan FB. Studies on the standardization of mistletoe preparations. *Oncology* 1986; 43:16-22.